Amitriptyline vs. pregabalin in painful diabetic neuropathy: a randomized double blind clinical trial

• DOI: 10.1111/j.1464-5491.2009.02806.x
• Publication Date: 2009-07-31T08:07:58Z
• Authors: D. Bansal; A. Bhansali; D. Hota; A. Chakrabarti; P. Dutta
• Keywords: Pregabalin; McGill Pain Questionnaire; Diabetic Neuropathy; Crossover study; Clinical Global Impression

Abstract Aims To compare the efficacy and safety of pregabalin amitriptyline in alleviating pain associated with diabetic peripheral neuropathy. Methods A randomized, double‐blind, crossover, active–control, clinical trial variable dose titration was carried out ( n = 51). Amitriptyline orally, at doses 10, 25 50 mg night‐time 75, 150 300 twice daily, by optional used. Each drug treatment 5 weeks. There a placebo washout period for 3 weeks between two drugs. Assessment relief, overall improvement adverse events were out. Results Good, moderate mild relief noted 21 (48%), 6 (13%) 7 (15%) patients on 15 (34%), (11%) 12 (27%) amitriptyline, respectively, patient’s global assessment safety. Patient physician’s assessment, McGill questionnaire, Likert scale Global Impression Change showed no significant difference treatments, although both treatments seen from first week. Of 52 reported, 34 (65.4%) drowsiness being commonest [in 19 (43%) patients]. Pregabalin caused 18 (25%), which most common nine (20%) patients. The preferred daily. Conclusions As there are few differences efficacy, daily might be alternative choice as it is fewer effects our population.